Full data shows China’s Sinovac vaccine candidate, “CoronaVac,” to be 50.38 percent effective against the Chinese coronavirus in late-stage trials, Brazilian state researchers revealed Tuesday, according to the Wall Street Journal.
The figure is nearly 30 percentage points lower than the 78 percent efficacy rate for CoronaVac which the São Paulo state government-funded Butantan Institute previously announced on January 7.
Butantan is currently running final-stage clinical trials for CoronaVac, a Chinese coronavirus vaccine candidate developed by China’s Sinovac Biotech. The institute submitted new data to Brazil’s federal health regulator at a press conference on January 12, listing CoronaVac’s efficacy rate as just under 50.4 percent.
CoronaVac’s previous efficacy rate of 78 percent “only included volunteers who suffered mild to severe cases” of the Chinese coronavirus, Butantan said Tuesday, according to the Wall Street Journal.
“When data from all volunteers is considered, including those who contracted ‘very mild’ cases of Covid-19 [Chinese coronavirus] and required
